ArdorComm Media Group

Contact Us
Thursday, April 2, 2026 12:41 PM
logo
Menu
logo

Health & Wellness Community

Diabetes Driving India’s Silent Liver Disease Crisis, Study Warns

/ Health & Wellness Community

A groundbreaking study has revealed that Type 2 diabetes is emerging as a major cause of advanced liver disease in India, often progressing unnoticed until it becomes life-threatening. Published in The Lancet, the DiaFib-Liver Study is the largest real-world research of its kind in a developing country, highlighting the liver as a critical yet overlooked organ at risk among diabetic patients. The study, which assessed 9,202 adults across 27 healthcare centres, found that nearly 25% of patients had significant liver fibrosis, while about 14% had advanced disease. Alarmingly, around 5% had already reached a stage suggestive of cirrhosis—despite showing no obvious symptoms. Experts note a shift in the primary causes of severe liver conditions, with diabetes and obesity now surpassing viral infections like Hepatitis B and C. The underlying mechanism involves fat accumulation in the liver, leading to insulin resistance, chronic inflammation, and eventual scarring. Interestingly, the research also challenges the belief that liver disease primarily affects overweight individuals. Cases were observed even among lean patients, with a phenomenon termed “burnt-out” liver disease—where fat diminishes as fibrosis worsens—making detection even more difficult. Given that liver damage often remains silent until advanced stages, researchers emphasize the need for improved screening. They recommend tools like the FIB-4 score, derived from routine blood tests, and FibroScan imaging for early detection, instead of relying solely on ultrasounds. Encouragingly, the study highlights that early-stage liver damage can be reversed. A 5% reduction in body weight may reverse fibrosis in many cases, while a 10% reduction can significantly slow disease progression. With India home to over 10 crore diabetics and millions more at risk, integrating liver health checks into diabetes care programs could be key to preventing a large-scale health crisis. Source: TNN

Diabetes Driving India’s Silent Liver Disease Crisis, Study Warns Read More »

India Among Nations with Highest Maternal Deaths in 2023 Despite Significant Progress: Global Study

/ Health & Wellness Community

A recent global analysis published in The Lancet Obstetrics, Gynaecology, and Women’s Health has highlighted that India remains among the nations with the highest number of maternal deaths in 2023, reporting approximately 24,700 fatalities. This corresponds to a maternal mortality ratio (MMR) of 116 deaths per one lakh live births. Other countries with significant figures include Pakistan with 10,300 deaths, and African nations such as Ethiopia and Nigeria reporting 11,900 and 32,900 deaths respectively. The study, conducted by researchers from the Institute for Health Metrics and Evaluation at the University of Washington along with global collaborators, notes that while maternal mortality has declined significantly over the past 30 years, the pace of improvement has slowed and disparities across regions persist. The findings are part of the Global Burden of Disease (GBD) 2023 assessment, which evaluates trends across 204 countries. In contrast, India’s latest Sample Registration System (SRS) data for 2021–23 shows a lower MMR of 88 per one lakh live births, reflecting continued national progress. Government sources also point out that India has achieved an 86% reduction in maternal mortality since 1990, surpassing the global average decline and aligning with its commitment to meet the Sustainable Development Goal (SDG) target of reducing MMR below 70 by 2030. Globally, maternal deaths stood at around 240,000 in 2023, with an MMR of 190.5—down by more than one-third from 1990 levels. However, over half of the countries studied are still above the SDG threshold. The leading causes of maternal deaths worldwide include severe bleeding and pregnancy-related hypertensive disorders. Experts emphasize that expanding access to antenatal care, ensuring safe childbirth services, strengthening emergency obstetric care, and improving postnatal follow-up can significantly reduce maternal deaths. The study also noted that the COVID-19 pandemic temporarily reversed progress, contributing to increased maternal mortality during its early phase. With less than five years left to achieve global targets, the report calls for renewed focus, stronger health systems, and sustained investments to accelerate progress in maternal health outcomes. Source: PTI

India Among Nations with Highest Maternal Deaths in 2023 Despite Significant Progress: Global Study Read More »

Medanta to Invest ₹550 Crore in 400-Bed Multi-Specialty Hospital in Varanasi

/ Health & Wellness Community

Medanta has announced plans to establish a 400-bed multi-specialty hospital in Varanasi, marking a significant expansion of its healthcare footprint in Uttar Pradesh. The upcoming facility will be developed under a built-to-suit lease agreement with Shripal Hospitality and its associates. While the partner will handle the construction of the hospital’s civil infrastructure according to Medanta’s standards, the hospital chain will invest approximately ₹550 crore towards medical equipment, interiors, and fit-outs. This new project is expected to further strengthen Medanta’s presence in the state. The group already operates a 950-bed flagship hospital in Lucknow and recently launched a 550-bed facility in Noida. With the addition of the Varanasi hospital, Medanta’s total bed capacity in Uttar Pradesh will increase to around 1,900. Commenting on the development, Dr. Naresh Trehan, Chairman and Managing Director of Medanta, stated that the expansion reflects the organisation’s commitment to improving access to advanced and patient-centric healthcare in densely populated regions. Echoing this, Pankaj Sahni, Group CEO of Medanta, highlighted that Varanasi remains an underserved market in terms of quality tertiary healthcare. He noted that most existing hospitals in the city operate at a smaller capacity of 50–150 beds, often forcing patients to travel to other cities for specialised and complex treatments. Source: Economic Times

Medanta to Invest ₹550 Crore in 400-Bed Multi-Specialty Hospital in Varanasi Read More »

Temasek-Backed Manipal Health Enterprises Files for IPO to Capitalise on Rising Healthcare Demand

/ Health & Wellness Community

Manipal Health Enterprises, a hospital network backed by Temasek, has filed draft papers for an initial public offering (IPO), aiming to raise ₹8,000 crore (approximately $852 million) through a fresh issue of shares. As part of the offering, existing investors are also planning to offload around 43.2 million shares, according to the company’s prospectus. The Bengaluru-headquartered healthcare provider is positioning itself to benefit from the growing demand for specialised medical services in India. Industry experts suggest that this segment is expected to drive significant growth in the country’s healthcare sector, which continues to attract strong interest from global investors such as Blackstone, Novo Nordisk, and KKR. Over the past few years, Manipal Health has expanded aggressively, emerging as a major consolidator in the healthcare space. One of its most notable recent acquisitions includes Sahyadri Hospitals, which it purchased for $700 million. The company plans to utilise the proceeds from the IPO to reduce its existing debt and fund the acquisition of Sahyadri Hospitals. However, the IPO comes amid challenging market conditions. Indian equity markets have seen a decline recently, influenced by global risk aversion, tightening liquidity, and continued foreign investor outflows. Despite these headwinds, Manipal Health is banking on strong long-term fundamentals in India’s healthcare sector to drive investor interest in its public offering. Source: Reuters

Temasek-Backed Manipal Health Enterprises Files for IPO to Capitalise on Rising Healthcare Demand Read More »

Climate Action Could Prevent 13.5 Million Air Pollution Deaths by 2050: Global Study

/ Health & Wellness Community

A new study published in The Lancet Global Health reveals that strong climate action aimed at limiting global warming to 2°C could prevent more than 13.5 million premature deaths caused by air pollution by 2050—primarily in low- and middle-income countries (LMICs). The research, led by experts including those from The University of Texas at Austin, highlights that the scale and distribution of health benefits depend significantly on how global climate mitigation efforts are shared among nations. According to the findings, a “least-cost” approach—where emissions are reduced wherever it is cheapest—places a heavier burden on LMICs. However, this model also delivers the greatest improvements in air quality in those regions, resulting in the highest number of lives saved. In contrast, an “equity-based” approach, where wealthier nations take on a larger share of emissions reduction, eases the financial burden on developing countries. But this could lead to nearly four million fewer lives saved, as emissions cuts may not occur in the most pollution-affected regions. Co-author Mark Budolfson noted a critical dilemma between climate justice and maximizing health outcomes, explaining that shifting mitigation responsibility to richer nations may unintentionally reduce life-saving air quality improvements in poorer countries. The study also evaluated a third scenario that combines equity with targeted air pollution controls in LMICs—such as reducing soot and sulphur dioxide emissions through advanced technologies in industries like power generation. This approach emerged as the most effective, balancing fairness with maximum health benefits. Another co-author, Noah Scovronick of Emory University, stressed the importance of designing climate policies that prioritize both justice and public health. He emphasized that developing nations must not miss the opportunity to achieve significant reductions in air pollution while transitioning to cleaner systems. The study underscores the need for global cooperation to craft climate strategies that are both equitable and life-saving. Source: PTI

Climate Action Could Prevent 13.5 Million Air Pollution Deaths by 2050: Global Study Read More »

Oura Debuts in India with Smart Ring 4, Targets Sleep Health Market

/ Health & Wellness Community

Finnish health-tech firm Oura Health has officially stepped into the Indian market with the launch of its latest wearable, the Oura Ring 4. With this move, the company enters a growing segment, competing with homegrown players like Noise and Ultrahuman. Alongside the launch, Oura highlighted insights from its “State of Sleep 2026” study, revealing concerning sleep patterns among Indian users. The findings suggest that India ranks among the lowest in sleep duration globally, with users averaging just 6 hours and 28 minutes per night—around 40 minutes less than those in the highest-sleeping countries. The report also indicates that Indians experience the least amount of REM and deep sleep, missing over an hour of REM sleep weekly compared to global averages. According to the company, increasingly fast-paced and digitally connected lifestyles are significantly impacting sleep quality in the country. The Oura Ring 4 is designed to monitor over 50 health and wellness indicators and works seamlessly with the Oura app on both iOS and Android devices. Equipped with advanced sensing technology, the ring adapts to individual physical traits such as finger shape and skin tone to deliver personalized insights. Crafted from titanium, the ring features recessed sensors for enhanced comfort, making it suitable for continuous wear, including during sleep. It is offered in 12 sizes ranging from 4 to 15 and comes in six finishes: Black, Silver, Stealth, Brushed Silver, Gold, and Rose Gold. The device will be available starting March 18 through Amazon and Croma outlets. Pricing begins at ₹28,900 for Black and Silver variants, while premium finishes are priced at ₹39,900. Users will also need to subscribe to an Oura membership plan, which is priced at ₹599 per month. Source: The Hindu  

Oura Debuts in India with Smart Ring 4, Targets Sleep Health Market Read More »

Blood Biomarker May Predict Women’s Dementia Risk 25 Years Before Symptoms: Study

/ Health & Wellness Community

A new study suggests that a simple blood test could help predict a woman’s risk of developing dementia up to 25 years before symptoms appear. Researchers identified a blood-based biomarker called phosphorylated tau 217 (p-tau217), a protein associated with the brain changes linked to Alzheimer’s disease. The study found that higher levels of p-tau217 were strongly linked with the later development of mild cognitive impairment and dementia among women who showed no signs of cognitive decline at the beginning of the research. “Our study suggests we may be able to identify women at elevated risk for dementia decades before symptoms emerge,” said lead author Aladdin H. Shadyab, associate professor of public health and medicine at University of California San Diego. According to Shadyab, such early detection could allow doctors to focus on prevention strategies and closer monitoring long before memory issues begin affecting daily life. The findings were published in JAMA Network Open and are based on data from the Women’s Health Initiative Memory Study, a large U.S. national study involving 2,766 women aged between 65 and 79 who were enrolled in the late 1990s and followed for up to 25 years. During the follow-up period, researchers tracked participants who developed memory or thinking problems, including dementia. Women with higher p-tau217 levels in their blood at the start of the study were found to have a significantly greater likelihood of developing dementia later in life. The risk increased as biomarker levels rose. The study also found that elevated p-tau217 levels were more strongly linked to poorer cognitive outcomes among women aged 70 and older, as well as among those carrying the APOE e4 genetic risk factor associated with Alzheimer’s disease. Additionally, the biomarker appeared to be more predictive among women who had been randomly assigned estrogen-plus-progestin hormone therapy compared to those given a placebo. Researchers noted that factors such as age, race, the APOE e4 gene, and hormone therapy use should be considered when examining the link between p-tau217 and cognitive decline. Senior author Linda K. McEvoy of the Kaiser Permanente Washington Health Research Institute said blood-based biomarkers like p-tau217 are particularly promising because they are far less invasive than traditional diagnostic methods such as brain imaging or spinal fluid tests. “This could significantly advance research into the causes of dementia and help scientists evaluate strategies that may reduce the risk of developing the condition,” McEvoy said. Source: PTI Photo Credit: Bogdanhoda

Blood Biomarker May Predict Women’s Dementia Risk 25 Years Before Symptoms: Study Read More »

217 Organ Transplant Hospitals Fail to Submit Data to National Registry in 2025

/ Health & Wellness Community

As many as 217 hospitals authorised to perform organ transplants across India did not submit their data to the National Organ and Tissue Transplant Registry Portal in 2025, the government informed the Rajya Sabha on Tuesday. Minister of State for Health Prataprao Jadhav stated that appropriate action against these hospitals will be taken by the respective state governments. In a written reply, the minister said that out of 804 hospitals registered to conduct organ transplantation, 217 failed to upload the required information on the registry portal during the year. Under the provisions of the Transplantation of Human Organs and Tissues Act, 1994, regulatory action against such institutions falls under the jurisdiction of state authorities where the hospitals are located. Hospital registrations for organ transplant procedures are handled by the appropriate authorities of the states and Union Territories. The National Organ and Tissue Transplant Registry Portal has been operational since 2015 and can be accessed by authorised users through the website of the National Organ and Tissue Transplant Organisation. According to data uploaded by hospitals and transplant centres on the portal, the waiting list for major organ transplants in India stood at 89,839 as of March 3, 2026. During 2025, a total of 20,019 organ transplant procedures were carried out nationwide. The central government is currently implementing the National Organ Transplant Programme, which focuses on strengthening infrastructure for transplantation services and promoting awareness about organ donation. As part of this initiative, Regional Organ and Tissue Transplant Organizations and State Organ and Tissue Transplant Organizations have been established across several states and Union Territories in the northern, eastern, and north-eastern regions of the country, with a few exceptions. Source: PTI Photo Credit: iStockphoto/Getty Images

217 Organ Transplant Hospitals Fail to Submit Data to National Registry in 2025 Read More »

Japan Approves World’s First Stem-Cell Treatment for Parkinson’s Disease

/ Health & Wellness Community

In a major medical breakthrough, Japan has approved pioneering stem-cell therapies for Parkinson’s disease and severe heart failure, marking the first time such treatments using induced pluripotent stem (iPS) cells will be commercially available. The therapies could begin reaching patients within months, according to reports and company statements. Pharmaceutical company Sumitomo Pharma announced that it has received approval to manufacture and sell Amchepry, a treatment designed to transplant stem cells into a patient’s brain to help manage Parkinson’s disease. The therapy aims to replace lost dopamine-producing cells, which are responsible for many of the motor symptoms associated with the condition. Meanwhile, Japan’s health ministry has also approved ReHeart, a treatment developed by medical startup Cuorips. The therapy uses sheets of heart muscle cells that can help regenerate blood vessels and improve heart function in patients suffering from severe heart failure. These therapies are based on groundbreaking research by Japanese scientist Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012 for discovering iPS cells—cells that can develop into almost any type of cell in the human body. Japan’s health minister Kenichiro Ueno said the government aims to ensure the treatments become available to patients as quickly as possible. “I hope this will bring relief to patients not only in Japan but around the world,” he said during a press briefing. According to the company, Amchepry has been granted conditional and time-limited approval, allowing faster access for patients while further data on safety and effectiveness continues to be gathered. This system is designed to accelerate the availability of innovative regenerative therapies. Clinical trials conducted by researchers at Kyoto University tested the treatment on seven Parkinson’s patients aged between 50 and 69. Each participant received either five million or ten million stem-cell-derived dopamine precursor cells implanted in both sides of the brain. The patients were monitored for two years, and the study reported no serious side effects. Four of the participants showed noticeable improvements in their symptoms. Parkinson’s disease is a progressive neurological disorder that affects movement and can cause tremors, stiffness, and difficulty with coordination. According to the Parkinson’s Foundation, around 10 million people worldwide live with the condition. Current treatments mainly manage symptoms but do not stop or reverse the disease. The use of iPS cells—created by reprogramming mature cells back into a versatile, stem-like state—has become one of the most promising areas in regenerative medicine. Japan’s approval of these therapies marks a significant step toward translating this research into real-world medical treatment. Source: AFP

Japan Approves World’s First Stem-Cell Treatment for Parkinson’s Disease Read More »

PM Narendra Modi Rolls Out Nationwide HPV Vaccination Drive for 14-Year-Old Girls

/ Health & Wellness Community

Prime Minister Narendra Modi on Saturday launched a nationwide Human Papillomavirus (HPV) vaccination campaign targeting 14-year-old girls. The initiative was inaugurated from Ajmer in Rajasthan on February 28, 2026. The cervical cancer prevention drive was formally introduced at a programme in Kayad, Ajmer, where several girls received the vaccine in the presence of the Prime Minister. He also interacted with beneficiaries during the event, highlighting the importance of preventive healthcare for young women. Under the campaign, a single-dose “Gardasil 4” vaccine — a quadrivalent HPV vaccine — will be administered. The vaccine offers protection against HPV types 16 and 18, which are the leading causes of cervical cancer, as well as types 6 and 11. The Union Health Ministry, in a communication issued to all States on February 25, confirmed that every 14-year-old girl across the country will receive a single dose of the vaccine free of cost. The vaccination will be carried out at government health facilities, including Ayushman Arogya Mandirs (Primary Health Centres), Community Health Centres, sub-district and district hospitals, as well as government medical colleges and hospitals. The nationwide rollout marks a significant step in India’s public health efforts to reduce the burden of cervical cancer through early immunisation and preventive care. Source: The Hindu

PM Narendra Modi Rolls Out Nationwide HPV Vaccination Drive for 14-Year-Old Girls Read More »